Enovis Corporation
ENOV | NYSE
$18.04
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$18.04
$0 (0.00%)
After-hours:
Sep 21, 2026, 5:55 PM ET
Company Profile
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Key Executives
| Name | Position |
|---|---|
| Damien McDonald | Chief Executive Officer & Director |
| Bradley J. Tandy | Senior Vice President & Chief Legal Officer |
| Phillip Benjamin Berry | Senior Vice President & Chief Financial Officer |
| John Kleckner | Vice President, Controller & Chief Accounting Officer |
| Kyle William Rose | Vice President of Investor Relations |
| Laura Singleton | Senior Vice President & Chief Human Resources Officer |
| Louie Vogt | Group President of Reconstructive |
| Oliver Engert | Chief Administrative Officer |
| Patricia A. Lang | Advisor |
| Terry Ross | Group President Prevention & Recovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 01, 2026 | 4 | Filing |
| Jun 26, 2026 | 11-K | Filing |
Enovis Corporation
| Country | United States |
| IPO Date | May 7, 2008 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 7,802 |
| CEO | Damien McDonald |
Contact Details
2711 Centerville Road Wilmington,
Delaware 19808 United States
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| SIC Code | 3842 |
Recent News
- 19 days ago / zacks.comWhat Makes Enovis (ENOV) a New Buy Stock
- 19 days ago / zacks.comEnovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- 20 days ago / zacks.comEnovis Boosts Surgical Robotics Portfolio With eCential Acquisition
- 21 days ago / seekingalpha.comEnovis Corporation (ENOV) M&A Call Transcript
- 21 days ago / marketbeat.comEnovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
- 21 days ago / prnewswire.comeCential Robotics Announces Binding Offer from Enovis
- 21 days ago / globenewswire.comEnovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
- 22 days ago / globenewswire.comEnovis to Participate in the 2026 Wells Fargo Healthcare Conference
- 1 month ago / seekingalpha.comEnovis Corporation: Arvis Is Disrupting The Health Care Industry
- 1 month ago / seekingalpha.comEnovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land
Add to Watchlist
Select watchlists to add or remove ENOV